Coverage at a glance
| Indication | Coverage |
|---|---|
| Obesity / weight management | Not covered |
Plan type: ACA Marketplace individual and family plans, including Ambetter and Oscar. Each indication below lists the BMI and clinical thresholds, the prior-authorization documentation, and the published policy it comes from.
Coverage by indication
Anti-obesity medications are excluded from Essential Health Benefits under Section 1927(d)(2) of the Social Security Act. A CMS clarification in January 2024 confirmed that medications approved solely for chronic weight management are not required EHB benefits. KFF analysis of 2024 federally facilitated Marketplace formularies found only 1 percent of plans cover Wegovy for obesity and 0 percent cover Zepbound for obesity. Of the rare plans that do cover obesity-indication GLP-1s, all require prior authorization. Ambetter, the Centene marketplace brand operating in 25 or more states, follows this federal exclusion across nearly all markets and plan tiers.
Source: KFF, Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans. KFF policy analysis (independent health-policy research; reviewed publicly available 2024 federally facilitated Marketplace formularies). Verified June 12, 2026.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list, then have your prescriber submit it.
- Start with the ACA Marketplace prior-authorization letter template, which cites this plan's policy and the diagnosis codes a reviewer looks for. Pick the indication that matches your clinical picture.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- If your plan does not cover the indication you need, compare cash-pay options in the cost guide and the cheapest legitimate programs.
Frequently asked questions
Does ACA Marketplace cover GLP-1 medications?
Usually no. ACA Marketplace plans rarely cover GLP-1s for weight loss. A KFF review of federally facilitated Marketplace formularies found that only 1 percent of plans cover Wegovy for obesity and none cover Zepbound for obesity. This reflects the published policy verified June 2026.
Why is GLP-1 medications not covered?
Anti-obesity medications are excluded from Essential Health Benefits under Section 1927(d)(2) of the Social Security Act. A CMS clarification in January 2024 confirmed that medications approved solely for chronic weight management are not required EHB benefits. KFF analysis of 2024 federally facilitated Marketplace formularies found only 1 percent of plans cover Wegovy for obesity and 0 percent cover Zepbound for obesity. Of the rare plans that do cover obesity-indication GLP-1s, all require prior authorization. Ambetter, the Centene marketplace brand operating in 25 or more states, follows this federal exclusion across nearly all markets and plan tiers.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources and the row is marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit, so those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
